Browsing Tag
Palatin Technologies
3 posts
Is the next wave of obesity drugs moving beyond GLP-1? What Palatin, Rhythm, and Zealand are betting on
Explore how Palatin Technologies, Rhythm Pharmaceuticals, and Zealand Pharma are shifting obesity drug development beyond GLP-1 into MC4R and amylin pathways. Read on.
Palatin Technologies to raise $15.8m in public offering; NYSE relisting expected Nov 12
Palatin Technologies regains NYSE American compliance and secures $15.8M for its oral MC4R obesity drug. Find out how the relisting and IND impact its biotech trajectory.
Palatin Technologies completes Phase 2 obesity trial with MC4R bremelanotide and GLP-1/GIP tirzepatide
Palatin Technologies, Inc. has announced the completion of its Phase 2 BMT-801 clinical trial, a study evaluating the…